Christine Hodgdon/leeoesterreich.org
Mar 16, 2025, 12:18
Christine Hodgdon: CHLOE study enrolling participants with HER2+ oligometastatic breast cancer
Christine Hodgdon, Co-founder of GRASP, shared a post on X:
“If you are living with HER2+ oligometastatic breast cancer (oligo = limited of mets), you may be eligible to participate in the CHLOE study, Yale Cancer Center.
Individuals (US and international) can now self refer!
More posts featuring Christine Hodgdon.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 16, 2025, 12:10
Mar 16, 2025, 12:02
Mar 16, 2025, 11:59
Mar 16, 2025, 11:44
Mar 16, 2025, 11:32
Mar 16, 2025, 11:32
Mar 16, 2025, 10:58
Mar 16, 2025, 10:13
Mar 16, 2025, 10:05